Mark P. Grillo
About Mark P. Grillo
Mark P. Grillo is the Scientific Director at Bristol Myers Squibb in Brisbane, California, with extensive experience in pharmacokinetics and drug metabolism research.
Current Role as Scientific Director
Mark P. Grillo holds the position of Scientific Director at Bristol Myers Squibb, based in Brisbane, California, United States. In this role, he applies his extensive expertise in drug metabolism and pharmacokinetics to advance the company’s research initiatives. His responsibilities encompass overseeing preclinical in vitro and in vivo studies, contributing to the development of new therapeutic strategies.
Previous Experience in Pharmaceutical Industry
Mark P. Grillo has amassed considerable experience in the pharmaceutical industry, having held notable positions at MyoKardia, Amgen, Merck, Pfizer, and AvMax. At MyoKardia, he served as a Staff Scientist for six years, engaged in significant research projects. His ten-year tenure at Amgen as Principal Scientist is marked by contributions to various research programs. Mark also worked at Pfizer twice as Principal Research Scientist, focusing on key research endeavors before moving to AvMax, where he was the Director for two years. His early career included a role as a Research Fellow at Merck.
Educational Background in Chemistry and Medicinal Chemistry
Mark P. Grillo’s academic journey began at the University of Minnesota Duluth, where he earned a B.S. in Chemistry. He advanced his studies at the University of Washington, achieving a Ph.D. in Medicinal Chemistry. His academic prowess further extended at the University of California, San Francisco, where he completed a seven-year postdoctoral fellowship in Pharmacy. This robust educational foundation underpins his significant contributions to pharmacokinetics and drug metabolism.
Contributions to Pharmacokinetics and Drug Metabolism Research
Throughout his career, Mark P. Grillo has made substantial contributions to the field of pharmacokinetics and drug metabolism. Notably, he co-authored a 2021 publication on the pharmacokinetic properties of danicamtiv, and a 2019 study on the characterization of mavacamten. Additionally, his 2015 publication focused on detecting reactive drug metabolites to mitigate drug toxicity potential. His research has significantly advanced the understanding of drug behaviors in the human body.
Engagement with Translational Medicine and Health Equity
In his professional endeavors, Mark P. Grillo actively participates in translational medicine, bridging the gap between laboratory research and patient care. He utilizes data analytics to enhance the precision of therapeutic interventions and is involved in developing Risk Evaluation and Mitigation Strategies (REMS) for medications. Beyond his scientific contributions, Mark advocates for policies that promote health equity and engages in initiatives aimed at improving patient access to medications.